Luuk F. P. Giesen
Research Subjects
Luuk F. P. Giesen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Robert de Jonge
Department of Laboratory Medicine Amsterdam University Medical Centre Amsterdam the Netherlands
2 shared publications Brooke M Katzman
Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN
1 shared publicationChristian M Hackeng
Department of Clinical Chemistry, St.Antonius Hospital , Nieuwegein
1 shared publicationFrederique M A Koopman
Department of Clinical Affairs, Vitestro , Utrecht
1 shared publication- Frederique M. A. Koopman
Department of Clinical Affairs, Vitestro, Europalaan 500, 3526 KS Utrecht, The Netherlands
1 shared publication Helena Chon
Department of Laboratory Medicine, Amsterdam University Medical Center , Amsterdam
1 shared publication
Latest Publications
- Open Access
- 17 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (22) , 3822
An Autonomous Robotic Phlebotomy Device: Extended Analytical Validation and Real-World Hemolysis Assessment
Background/Objectives: Automated phlebotomy may improve preanalytical quality and access to venous blood testing. Prior work evaluating the Aletta Autonomous Robotic Phlebotomy Device (ARPD) demonstrated analytical equivalence. This study expanded the initial analytical validation to additional blood collection tubes and analytes and also assessed real-world hemolysis rates. Methods: The study was conducted in three hospital outpatient phlebotomy departments, including a site with a high prevalence of (hemato-)oncology patients. The within-subject analytical validation study included Greiner VACUETTE (Cohort 1) and BD Vacutainer (Cohort 2) serum, lithium heparin, and EDTA tubes. Equivalence of potassium, lactate dehydrogenase, hemolysis index, and complete blood count (CBC) with differential between paired ARPD-collected and manually collected samples was assessed using Passing–Bablok regression. Real-world ARPD hemolysis (>0.5 g/L free hemoglobin) rates were determined in a separate cohort (Cohort 3) and compared with site-specific manual hemolysis rates. Results: In the analytical validation study, 119 patients were included in the analysis (Cohort 1, n = 52; Cohort 2, n = 67). All tests met the predefined acceptability criteria. The hemolysis index was statistically significantly lower in ARPD-collected lithium heparin samples in Cohort 1. In real-world use (1368 ARPD venipunctures), the ARPD hemolysis rate was 0.0% (95% CI: 0.0–0.3%), significantly lower than manual phlebotomy (1.6%, p = 0.025). Conclusions: The study demonstrated analytical equivalence in a clinically complex population and found reduced ARPD hemolysis rates. The results further substantiate that the ARPD could improve patient care by reducing preanalytical errors.
- 17 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (22) , 3822
Open AccessAn Autonomous Robotic Phlebotomy Device: Extended Analytical Validation and Real-World Hemolysis Assessment
Background/Objectives: Automated phlebotomy may improve preanalytical quality and access to venous blood testing. Prior work evaluating the Aletta Autonomous Robotic Phlebotomy Device (ARPD) demonstrated analytical equivalence. This study expanded the initial analytical validation to additional blood collection tubes and analytes and also assessed real-world hemolysis rates. Methods: The study was conducted in three hospital outpatient phlebotomy departments, including a site with a high prevalence of (hemato-)oncology patients. The within-subject analytical validation study included Greiner VACUETTE (Cohort 1) and BD Vacutainer (Cohort 2) serum, lithium heparin, and EDTA tubes. Equivalence of potassium, lactate dehydrogenase, hemolysis index, and complete blood count (CBC) with differential between paired ARPD-collected and manually collected samples was assessed using Passing–Bablok regression. Real-world ARPD hemolysis (>0.5 g/L free hemoglobin) rates were determined in a separate cohort (Cohort 3) and compared with site-specific manual hemolysis rates. Results: In the analytical validation study, 119 patients were included in the analysis (Cohort 1, n = 52; Cohort 2, n = 67). All tests met the predefined acceptability criteria. The hemolysis index was statistically significantly lower in ARPD-collected lithium heparin samples in Cohort 1. In real-world use (1368 ARPD venipunctures), the ARPD hemolysis rate was 0.0% (95% CI: 0.0–0.3%), significantly lower than manual phlebotomy (1.6%, p = 0.025). Conclusions: The study demonstrated analytical equivalence in a clinically complex population and found reduced ARPD hemolysis rates. The results further substantiate that the ARPD could improve patient care by reducing preanalytical errors.
- Open Access
- 10 April 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (8) , 845-856
Performance, Safety, and Patient Experience of an Autonomous Robotic Phlebotomy Device: A Multicenter Trial
Background: Automated phlebotomy has the potential to improve patient outcomes and address phlebotomist workforce challenges. The Autonomous Blood Drawing Optimization and Performance Testing trial (ADOPT, ClinicalTrials.gov NCT05878483) assesses performance, safety, and patient experience of an autonomous robotic phlebotomy device (ARPD) that utilizes multimodal imaging. Methods: Patients were recruited from outpatient phlebotomy departments in the Netherlands. In cohort 1, analytical equivalence was assessed by comparing within-subject test results from ARPD-collected and manually collected samples using Passing–Bablok regression analysis. In cohort 2, the ARPD was assessed in routine use. The primary performance endpoint was first-stick success rate; the primary safety endpoint was the rate of adverse events. Exploratory endpoints assessed pain and patient preference. Results: One hundred fifty-three patients were enrolled in cohort 1. No statistically significant differences were observed in activated partial thromboplastin time, prothrombin time, lactate dehydrogenase, aspartate transaminase, or platelet count, indicating analytical equivalence. A total of 1633 patients were enrolled in cohort 2. The overall first-stick success rate, in patients where the ARPD could identify a suitable vein, was 94.5% (95% CI, 93.3–95.5) and remained high in patients with difficult venous access (92.7%), obesity (97.4%), and age ≥65 years (93.4%). Adverse events, all mild, occurred at a rate of 0.6%. Ninety percent of patients reported far less (19%), less (32%), or similar pain (39%) compared with manual phlebotomy. Eighty-two percent indicated they would strongly prefer (16%) or prefer (31%) use of the ARPD in the future or had no preference (35%). Conclusions: Automated phlebotomy using the ARPD shows a favorable performance and safety profile and may improve patient experience. ClinicalTrials.gov Registration Number: NCT05878483
- 10 April 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (8) , 845-856
Open AccessPerformance, Safety, and Patient Experience of an Autonomous Robotic Phlebotomy Device: A Multicenter Trial
Background: Automated phlebotomy has the potential to improve patient outcomes and address phlebotomist workforce challenges. The Autonomous Blood Drawing Optimization and Performance Testing trial (ADOPT, ClinicalTrials.gov NCT05878483) assesses performance, safety, and patient experience of an autonomous robotic phlebotomy device (ARPD) that utilizes multimodal imaging. Methods: Patients were recruited from outpatient phlebotomy departments in the Netherlands. In cohort 1, analytical equivalence was assessed by comparing within-subject test results from ARPD-collected and manually collected samples using Passing–Bablok regression analysis. In cohort 2, the ARPD was assessed in routine use. The primary performance endpoint was first-stick success rate; the primary safety endpoint was the rate of adverse events. Exploratory endpoints assessed pain and patient preference. Results: One hundred fifty-three patients were enrolled in cohort 1. No statistically significant differences were observed in activated partial thromboplastin time, prothrombin time, lactate dehydrogenase, aspartate transaminase, or platelet count, indicating analytical equivalence. A total of 1633 patients were enrolled in cohort 2. The overall first-stick success rate, in patients where the ARPD could identify a suitable vein, was 94.5% (95% CI, 93.3–95.5) and remained high in patients with difficult venous access (92.7%), obesity (97.4%), and age ≥65 years (93.4%). Adverse events, all mild, occurred at a rate of 0.6%. Ninety percent of patients reported far less (19%), less (32%), or similar pain (39%) compared with manual phlebotomy. Eighty-two percent indicated they would strongly prefer (16%) or prefer (31%) use of the ARPD in the future or had no preference (35%). Conclusions: Automated phlebotomy using the ARPD shows a favorable performance and safety profile and may improve patient experience. ClinicalTrials.gov Registration Number: NCT05878483